{"transactions":[{"id":4617917,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T20:15:14.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":6602,"price":14.12,"value":93220.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":132650,"source":{"system":"sec-edgar","filing":"0001030575-26-000014","document":"form4-09152026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000103057526000014/form4-09152026_040901.xml","form_type":"4"}},{"id":4617916,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T20:15:14.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":31888,"price":14.12,"value":450258.56,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":640610,"source":{"system":"sec-edgar","filing":"0001030575-26-000014","document":"form4-09152026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000103057526000014/form4-09152026_040901.xml","form_type":"4"}},{"id":4617915,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T20:15:14.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":1750,"price":13.99,"value":24482.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":139252,"source":{"system":"sec-edgar","filing":"0001030575-26-000014","document":"form4-09152026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000103057526000014/form4-09152026_040901.xml","form_type":"4"}},{"id":4617914,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T20:15:14.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":8450,"price":13.99,"value":118215.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":672498,"source":{"system":"sec-edgar","filing":"0001030575-26-000014","document":"form4-09152026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000103057526000014/form4-09152026_040901.xml","form_type":"4"}},{"id":673228,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T16:30:08.000Z","date":"2026-08-26","kind":"sale","planned":true,"acquired":false,"shares":51,"price":13.96,"value":711.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.955 to $13.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":141002,"source":{"system":"sec-edgar","filing":"0001030575-26-000012","document":"form4-08282026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000012/form4-08282026_040801.xml","form_type":"4"}},{"id":673227,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T16:30:08.000Z","date":"2026-08-26","kind":"sale","planned":true,"acquired":false,"shares":249,"price":13.96,"value":3476.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.955 to $13.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":680948,"source":{"system":"sec-edgar","filing":"0001030575-26-000012","document":"form4-08282026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000012/form4-08282026_040801.xml","form_type":"4"}},{"id":679218,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-21T20:20:01.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":4884,"price":14,"value":68376.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":141053,"source":{"system":"sec-edgar","filing":"0001030575-26-000010","document":"form4-08212026_080856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000010/form4-08212026_080856.xml","form_type":"4"}},{"id":679217,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-21T20:20:01.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":23584,"price":14,"value":330176.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":681197,"source":{"system":"sec-edgar","filing":"0001030575-26-000010","document":"form4-08212026_080856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000010/form4-08212026_080856.xml","form_type":"4"}},{"id":688298,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-13T21:04:38.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":368,"price":13.96,"value":5137.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":145937,"source":{"system":"sec-edgar","filing":"0001030575-26-000008","document":"form4-08132026_090834.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000008/form4-08132026_090834.xml","form_type":"4"}},{"id":688297,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-13T21:04:38.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":1775,"price":13.96,"value":24779.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":704781,"source":{"system":"sec-edgar","filing":"0001030575-26-000008","document":"form4-08132026_090834.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000008/form4-08132026_090834.xml","form_type":"4"}},{"id":713920,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T22:04:30.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":8506,"price":13.96,"value":118743.76,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.05 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":146305,"source":{"system":"sec-edgar","filing":"0001030575-26-000006","document":"form4-07072026_100726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000006/form4-07072026_100726.xml","form_type":"4"}},{"id":713919,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T22:04:30.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":817,"price":13.96,"value":11405.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.05 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":706556,"source":{"system":"sec-edgar","filing":"0001030575-26-000006","document":"form4-07072026_100726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000006/form4-07072026_100726.xml","form_type":"4"}},{"id":713918,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T22:04:30.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":14745,"price":14.03,"value":206872.35,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":154811,"source":{"system":"sec-edgar","filing":"0001030575-26-000006","document":"form4-07072026_100726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000006/form4-07072026_100726.xml","form_type":"4"}},{"id":713917,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T22:04:30.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":85955,"price":14.03,"value":1205948.65,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":707373,"source":{"system":"sec-edgar","filing":"0001030575-26-000006","document":"form4-07072026_100726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000006/form4-07072026_100726.xml","form_type":"4"}},{"id":728079,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":114,"price":14.98,"value":1707.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.97 to $15.10 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":169556,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728078,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":6979,"price":14.6,"value":101893.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.88 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":169670,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728077,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":666,"price":14.98,"value":9976.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.97 to $15.10 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":793328,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728076,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":40679,"price":14.6,"value":593913.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.88 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":793994,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728075,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":17426,"price":14.25,"value":248320.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (4), (5) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":176649,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728074,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":101579,"price":14.25,"value":1447500.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (4), (5) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":834673,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728073,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":580,"price":13.95,"value":8091.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":194075,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728072,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":3382,"price":13.95,"value":47178.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":936252,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":742134,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T21:58:03.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":14677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":14677,"derivative":{"exercise_price":10.59,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":14677},"source":{"system":"sec-edgar","filing":"0001193125-26-267996","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000119312526267996/ownership.xml","form_type":"4"}},{"id":757646,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T21:35:05.000Z","date":"2026-05-28","kind":"sale","planned":true,"acquired":false,"shares":419,"price":13.95,"value":5845.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":194655,"source":{"system":"sec-edgar","filing":"0001030575-26-000002","document":"form4-06012026_050601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000002/form4-06012026_050601.xml","form_type":"4"}},{"id":757645,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T21:35:05.000Z","date":"2026-05-28","kind":"sale","planned":true,"acquired":false,"shares":2441,"price":13.95,"value":34051.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":939634,"source":{"system":"sec-edgar","filing":"0001030575-26-000002","document":"form4-06012026_050601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000002/form4-06012026_050601.xml","form_type":"4"}},{"id":1114027,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:23:04.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":6010,"derivative":{"exercise_price":14.87,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":6010},"source":{"system":"sec-edgar","filing":"0000950170-25-085424","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000095017025085424/ownership.xml","form_type":"4"}},{"id":1482435,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T21:25:10.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":5190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Atlas XI and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5190,"derivative":{"exercise_price":42.19,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":5190},"source":{"system":"sec-edgar","filing":"0000950170-24-072564","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000095017024072564/ownership.xml","form_type":"4"}},{"id":1485426,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-10T20:15:09.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":17520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 7, 2025 or (ii) the date of the next annual meeting; provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":17520,"derivative":{"exercise_price":1.75,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":17520},"source":{"system":"sec-edgar","filing":"0000950170-24-071303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000095017024071303/ownership.xml","form_type":"4"}},{"id":1537039,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-23T21:25:47.000Z","date":"2024-04-22","kind":"grant","planned":false,"acquired":true,"shares":17857,"price":56,"value":999992.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":195074,"source":{"system":"sec-edgar","filing":"0001415889-24-011388","document":"form4-04232024_090441.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000141588924011388/form4-04232024_090441.xml","form_type":"4"}},{"id":1747835,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T02:09:10.000Z","date":"2023-11-03","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option vest in three equal annual installments commencing from November 3, 2023, subject to the Reporting Person's continued service on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"The Reporting Person is a member of Atlas XI and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein, if any."}],"balance_after":16000,"derivative":{"exercise_price":14.98,"expiration_date":"2033-11-02","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-23-060597","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000095017023060597/ownership.xml","form_type":"4"}},{"id":1747834,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-08T02:09:10.000Z","date":"2023-11-03","kind":"grant","planned":false,"acquired":true,"shares":177217,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Received in exchange for Legacy Korro common stock issued in the private placement completed immediately prior to the Merger."},{"field":"shares","element":"transactionShares","label":"F4","text":"Received in exchange for Legacy Korro common stock issued in the private placement completed immediately prior to the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for Legacy Korro common stock issued in the private placement completed immediately prior to the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"Atlas Opportunity II\"). Atlas Venture Associates Opportunity II, L.P. (\"Associates II\") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC (\"Associates II LLC\") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":177217,"source":{"system":"sec-edgar","filing":"0000950170-23-060597","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000095017023060597/ownership.xml","form_type":"4"}},{"id":1747833,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-08T02:09:10.000Z","date":"2023-11-03","kind":"grant","planned":false,"acquired":true,"shares":942075,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received in exchange for (i) 3,000,000 shares of common stock, (ii) 4,000,000 shares of Series Seed 1 Preferred Stock, (iii) 2,000,000 shares of Series Seed 2 Preferred Stock, (iv) 1,538,462 shares of Series Seed 3 Preferred Stock, (v) 5,357,142 shares of Series A Preferred Stock and (vi) 3,064,273 shares of Series B Preferred Stock of Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., \"Legacy Korro\") pursuant to an Agreement and Plan of Merger dated as of July 14, 2023 (the \"Merger Agreement\") by and among Legacy Korro, the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"). Under the terms of the Merger Agreement, on November 3, 2023, Merger Sub merged with and into Legacy Korro (the \"Merger\"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing of the Merger, each share of Legacy Korro common stock was converted into the right to receive 0.049688 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc."},{"field":"shares","element":"transactionShares","label":"F1","text":"Received in exchange for (i) 3,000,000 shares of common stock, (ii) 4,000,000 shares of Series Seed 1 Preferred Stock, (iii) 2,000,000 shares of Series Seed 2 Preferred Stock, (iv) 1,538,462 shares of Series Seed 3 Preferred Stock, (v) 5,357,142 shares of Series A Preferred Stock and (vi) 3,064,273 shares of Series B Preferred Stock of Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., \"Legacy Korro\") pursuant to an Agreement and Plan of Merger dated as of July 14, 2023 (the \"Merger Agreement\") by and among Legacy Korro, the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"). Under the terms of the Merger Agreement, on November 3, 2023, Merger Sub merged with and into Legacy Korro (the \"Merger\"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from Footnote 1) Upon the closing of the Merger, each share of Legacy Korro common stock was converted into the right to receive 0.049688 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for (i) 3,000,000 shares of common stock, (ii) 4,000,000 shares of Series Seed 1 Preferred Stock, (iii) 2,000,000 shares of Series Seed 2 Preferred Stock, (iv) 1,538,462 shares of Series Seed 3 Preferred Stock, (v) 5,357,142 shares of Series A Preferred Stock and (vi) 3,064,273 shares of Series B Preferred Stock of Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., \"Legacy Korro\") pursuant to an Agreement and Plan of Merger dated as of July 14, 2023 (the \"Merger Agreement\") by and among Legacy Korro, the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"). Under the terms of the Merger Agreement, on November 3, 2023, Merger Sub merged with and into Legacy Korro (the \"Merger\"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Upon the closing of the Merger, each share of Legacy Korro common stock was converted into the right to receive 0.049688 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"Associates XI\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"Associates XI LLC\") is the general partner of Associates XI. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":942075,"source":{"system":"sec-edgar","filing":"0000950170-23-060597","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000095017023060597/ownership.xml","form_type":"4"}},{"id":1857615,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T20:30:14.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":17520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 9, 2024 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":17520,"derivative":{"exercise_price":6.51,"expiration_date":"2033-06-09","underlying":"Common Stock","underlying_shares":17520},"source":{"system":"sec-edgar","filing":"0000899243-23-015445","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924323015445/doc4.xml","form_type":"4"}},{"id":2230413,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T22:33:36.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":7688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reporting person is a member of Atlas Venture Associates IX, LLC (\"AVA IX LLC\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":7688,"derivative":{"exercise_price":38.49,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":7688},"source":{"system":"sec-edgar","filing":"0001209191-22-037598","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919122037598/doc4.xml","form_type":"4"}},{"id":2230412,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-16T22:33:36.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":5197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":7291,"source":{"system":"sec-edgar","filing":"0001209191-22-037598","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919122037598/doc4.xml","form_type":"4"}},{"id":2234610,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T22:08:56.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":13419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the Reporting Person, a director of the Issuer, resigns from the Board or otherwise ceases to service as a director."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":13419,"derivative":{"exercise_price":4.85,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":13419},"source":{"system":"sec-edgar","filing":"0000899243-22-022238","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924322022238/doc4.xml","form_type":"4"}},{"id":2460003,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-23T23:43:14.000Z","date":"2021-12-21","kind":"grant","acquired":true,"shares":13419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest (1) 25% on December 21, 2022, and the remaining shall vest in equal monthly installments over the next 36 months."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":13419,"derivative":{"exercise_price":14.92,"expiration_date":"2031-12-21","underlying":"Common Stock","underlying_shares":13419},"source":{"system":"sec-edgar","filing":"0000899243-21-049693","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924321049693/doc4.xml","form_type":"4"}},{"id":2473969,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-15T01:29:44.000Z","date":"2021-12-14","kind":"sale","acquired":false,"shares":5959,"price":14,"value":83426.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1241935,"source":{"system":"sec-edgar","filing":"0001209191-21-069645","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919121069645/doc4.xml","form_type":"4"}},{"id":2473968,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-15T01:29:44.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":8330,"price":14.64,"value":121951.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1247894,"source":{"system":"sec-edgar","filing":"0001209191-21-069645","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919121069645/doc4.xml","form_type":"4"}},{"id":2473967,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-15T01:29:44.000Z","date":"2021-12-10","kind":"sale","acquired":false,"shares":11989,"price":15.03,"value":180194.67,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1256224,"source":{"system":"sec-edgar","filing":"0001209191-21-069645","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919121069645/doc4.xml","form_type":"4"}},{"id":2473966,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-15T01:29:44.000Z","date":"2021-03-30","kind":"purchase","acquired":true,"shares":125000,"price":16,"value":2000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"Atlas Venture Opportunity Fund I\"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":874634,"source":{"system":"sec-edgar","filing":"0001209191-21-069645","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919121069645/doc4.xml","form_type":"4"}},{"id":2571241,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T23:23:37.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":37800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on March 7, 2018, with 25% of the shares underlying the option vesting on March 7, 2019 and thereafter 2.0833% vesting monthly until March 7, 2022."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":8.34,"expiration_date":"2028-03-06","underlying":"Common Stock","underlying_shares":37800},"source":{"system":"sec-edgar","filing":"0001209191-21-056045","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919121056045/doc4.xml","form_type":"4"}},{"id":2571240,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T23:23:37.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":20.43,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-056045","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919121056045/doc4.xml","form_type":"4"}},{"id":2571239,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T23:23:37.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":18900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":15.33,"expiration_date":"2030-06-15","underlying":"Common Stcok","underlying_shares":18900},"source":{"system":"sec-edgar","filing":"0001209191-21-056045","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919121056045/doc4.xml","form_type":"4"}},{"id":2571238,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T23:23:37.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":18900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on June 18, 2019.  The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"This stock option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this stock option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":10.2,"expiration_date":"2029-06-17","underlying":"Common Stock","underlying_shares":18900},"source":{"system":"sec-edgar","filing":"0001209191-21-056045","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919121056045/doc4.xml","form_type":"4"}},{"id":2571237,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-14T23:23:37.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":2055063,"price":38,"value":78092394.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the \"Tender Offer\"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021."},{"field":"shares","element":"transactionShares","label":"F1","text":"As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the \"Tender Offer\"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"1,872,115 of these shares are held directly by Atlas Venture Fund VIII, L.P. (\"Atlas VIII'').  182,948 of these shares are held directly by Atlas Venture Associates VIII, L.P. (\"AVA VIII LP\"), the general partner of Atlas VIII.  These shares were previously received by AVA VIII LP in a pro-rata stock distribution pursuant to a Rule 10b5-1 plan established by Atlas VIII.  Atlas Venture Associates VIII, Inc. (\"AVA VIII INC\") is the sole general partner of AVA VIII LP.  Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII and Atlas VIII LP, except to the extent of his pecuniary interest therein, if any.  This report shall not be deemed to be an admission that Dr. Formela is the beneficial owner of such shares for the purposes of Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-056045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919121056045/doc4.xml","form_type":"4"}},{"id":2598465,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-08-18T20:41:29.000Z","date":"2021-08-17","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option will vest and become exercisable in full on August 17, 2022 subject to the Reporting Person's continued service as a director through the vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person is a member of Atlas Venture Associates IX, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership to the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":7500,"derivative":{"exercise_price":13.69,"expiration_date":"2031-08-17","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-21-033456","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924321033456/doc4.xml","form_type":"4"}},{"id":2652328,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":6149,"price":143.45,"value":882074.05,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $143.32 - $144.22, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (19) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652327,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":13556,"price":142.88,"value":1936881.28,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $142.32 - $143.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (18) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":16149,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652326,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":8420,"price":141.66,"value":1192777.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $141.32 - $142.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (17) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":29705,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652325,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":8027,"price":140.8,"value":1130201.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $140.32 - $141.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (16) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":38125,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652324,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":52320,"price":139.96,"value":7322707.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $139.32 - $140.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (15) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":46152,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652323,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":4201,"price":138.58,"value":582174.58,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $138.32 - $139.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (14) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":98472,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652322,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":5400,"price":138.05,"value":745470.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $137.32 - $138.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (13) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":102673,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652321,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":3033,"price":137.01,"value":415551.33,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $136.32 - $137.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (12) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":108073,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652320,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":21893,"price":135.83,"value":2973726.19,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $135.32 - $136.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (11) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":111106,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652319,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":30831,"price":134.86,"value":4157868.66,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $134.32 - $135.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (10) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":132999,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652318,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":36519,"price":133.77,"value":4885146.63,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $133.32 - $134.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (9) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":163830,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652317,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":56188,"price":132.77,"value":7460080.76,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $132.32 - $133.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":200349,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652316,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":53823,"price":131.82,"value":7094947.86,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.32 - $132.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":256537,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652315,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":66468,"price":130.79,"value":8693349.72,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.32 - $131.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":310360,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652314,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":48724,"price":129.88,"value":6328273.12,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.32 - $130.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":376828,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652313,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":56280,"price":128.77,"value":7247175.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.32 - $129.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":425552,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652312,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":55525,"price":127.79,"value":7095539.75,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.32 - $128.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":481832,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2652311,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T13:48:30.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":26019,"price":127.02,"value":3304933.38,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.32 - $127.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":537357,"source":{"system":"sec-edgar","filing":"0001104659-21-086607","document":"tm2120917-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921086607/tm2120917-1_4seq1.xml","form_type":"4"}},{"id":2655112,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-25T22:05:53.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":3382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 23, 2021 with respect to 3,382 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":3382,"derivative":{"exercise_price":83.59,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":3382},"source":{"system":"sec-edgar","filing":"0001209191-21-043374","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919121043374/doc4.xml","form_type":"4"}},{"id":2655111,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-25T22:05:53.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":2094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":2094,"source":{"system":"sec-edgar","filing":"0001209191-21-043374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919121043374/doc4.xml","form_type":"4"}},{"id":2664464,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (right to buy)","published_at":"2021-06-18T01:39:34.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Advisors, Inc. and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest\ntherein, if any."}],"balance_after":20000,"derivative":{"exercise_price":20.43,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-041811","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919121041811/doc4.xml","form_type":"4"}},{"id":2668969,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T13:51:28.000Z","date":"2021-06-14","kind":"sale","acquired":false,"shares":653,"price":89.25,"value":58280.25,"ownership":{"direct":false,"nature":"1See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.25 - $89.26, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":563376,"source":{"system":"sec-edgar","filing":"0001104659-21-081255","document":"tm2119750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921081255/tm2119750-1_4seq1.xml","form_type":"4"}},{"id":2668968,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T13:51:28.000Z","date":"2021-06-14","kind":"sale","acquired":false,"shares":13309,"price":88.7,"value":1180508.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.23 - $89.17, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":564029,"source":{"system":"sec-edgar","filing":"0001104659-21-081255","document":"tm2119750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921081255/tm2119750-1_4seq1.xml","form_type":"4"}},{"id":2668967,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T13:51:28.000Z","date":"2021-06-14","kind":"sale","acquired":false,"shares":93102,"price":87.75,"value":8169700.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.23 - $88.22, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":577338,"source":{"system":"sec-edgar","filing":"0001104659-21-081255","document":"tm2119750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921081255/tm2119750-1_4seq1.xml","form_type":"4"}},{"id":2668966,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T13:51:28.000Z","date":"2021-06-14","kind":"sale","acquired":false,"shares":47422,"price":86.73,"value":4112910.06,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.23 - $87.22, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":670440,"source":{"system":"sec-edgar","filing":"0001104659-21-081255","document":"tm2119750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921081255/tm2119750-1_4seq1.xml","form_type":"4"}},{"id":2668965,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T13:51:28.000Z","date":"2021-06-14","kind":"sale","acquired":false,"shares":16293,"price":85.92,"value":1399894.56,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.23 - $86.21, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":717862,"source":{"system":"sec-edgar","filing":"0001104659-21-081255","document":"tm2119750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921081255/tm2119750-1_4seq1.xml","form_type":"4"}},{"id":2668964,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T13:51:28.000Z","date":"2021-06-11","kind":"sale","acquired":false,"shares":1875,"price":85.98,"value":161212.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.90 - $86.08, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":734155,"source":{"system":"sec-edgar","filing":"0001104659-21-081255","document":"tm2119750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921081255/tm2119750-1_4seq1.xml","form_type":"4"}},{"id":2668963,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T13:51:28.000Z","date":"2021-06-11","kind":"sale","acquired":false,"shares":29071,"price":85.18,"value":2476267.78,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.90 - $85.89, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":736030,"source":{"system":"sec-edgar","filing":"0001104659-21-081255","document":"tm2119750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921081255/tm2119750-1_4seq1.xml","form_type":"4"}},{"id":2734789,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-01T00:55:15.000Z","date":"2021-04-29","kind":"sale","acquired":false,"shares":4513,"price":85.43,"value":385545.59,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.93 - $85.90, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":765101,"source":{"system":"sec-edgar","filing":"0001104659-21-059347","document":"tm2114552-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921059347/tm2114552-2_4seq1.xml","form_type":"4"}},{"id":2737468,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-28T23:51:49.000Z","date":"2021-04-28","kind":"sale","acquired":false,"shares":29740,"price":86.12,"value":2561208.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.90 - $86.39, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":769614,"source":{"system":"sec-edgar","filing":"0001104659-21-056726","document":"tm2114552-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921056726/tm2114552-1_4seq1.xml","form_type":"4"}},{"id":2737467,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-28T23:51:49.000Z","date":"2021-04-28","kind":"sale","acquired":false,"shares":102186,"price":85.4,"value":8726684.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.90 - $85.89, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":799354,"source":{"system":"sec-edgar","filing":"0001104659-21-056726","document":"tm2114552-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921056726/tm2114552-1_4seq1.xml","form_type":"4"}},{"id":2737466,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-28T23:51:49.000Z","date":"2021-04-27","kind":"sale","acquired":false,"shares":61680,"price":87.08,"value":5371094.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.90 - $87.69, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":901540,"source":{"system":"sec-edgar","filing":"0001104659-21-056726","document":"tm2114552-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921056726/tm2114552-1_4seq1.xml","form_type":"4"}},{"id":2737465,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-28T23:51:49.000Z","date":"2021-04-27","kind":"sale","acquired":false,"shares":68836,"price":86.41,"value":5948118.76,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.90 - $86.89, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":963220,"source":{"system":"sec-edgar","filing":"0001104659-21-056726","document":"tm2114552-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921056726/tm2114552-1_4seq1.xml","form_type":"4"}},{"id":2737464,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-28T23:51:49.000Z","date":"2021-04-27","kind":"sale","acquired":false,"shares":79714,"price":85.39,"value":6806778.46,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.90 - $85.89, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1032056,"source":{"system":"sec-edgar","filing":"0001104659-21-056726","document":"tm2114552-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921056726/tm2114552-1_4seq1.xml","form_type":"4"}},{"id":2737463,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-28T23:51:49.000Z","date":"2021-04-26","kind":"sale","acquired":false,"shares":806,"price":84.93,"value":68453.58,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.90 - $84.98, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1111770,"source":{"system":"sec-edgar","filing":"0001104659-21-056726","document":"tm2114552-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921056726/tm2114552-1_4seq1.xml","form_type":"4"}},{"id":2754684,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-07T18:14:37.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":800,"price":84.98,"value":67984.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.93 - $85.10, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1112576,"source":{"system":"sec-edgar","filing":"0001104659-21-047492","document":"tm2112406-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921047492/tm2112406-1_4seq1.xml","form_type":"4"}},{"id":2764839,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-01T22:23:14.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":5362888,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"Atlas Opportunity I\"). Atlas Venture Associates Opportunity I, L.P. (\"Associates I\") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC (\"Associates I LLC\") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":749634},"source":{"system":"sec-edgar","filing":"0000899243-21-014393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924321014393/doc4.xml","form_type":"4"}},{"id":2764838,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2021-04-01T22:23:14.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":7863094,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"Associates XI\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"Associates XI LLC\") is the general partner of Associates XI. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1099118},"source":{"system":"sec-edgar","filing":"0000899243-21-014393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924321014393/doc4.xml","form_type":"4"}},{"id":2764837,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2021-04-01T22:23:14.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":11258117,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas X\"). Atlas Venture Associates X, L.P. (\"Associates X\") is the general partner of Atlas X. Atlas Venture Associates X, LLC (\"Associates X LLC\") is the general partner of Associates X. The Reporting Person is a member of Associates X LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1573682},"source":{"system":"sec-edgar","filing":"0000899243-21-014393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924321014393/doc4.xml","form_type":"4"}},{"id":2764836,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-04-01T22:23:14.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":9499999,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas X\"). Atlas Venture Associates X, L.P. (\"Associates X\") is the general partner of Atlas X. Atlas Venture Associates X, LLC (\"Associates X LLC\") is the general partner of Associates X. The Reporting Person is a member of Associates X LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1327927},"source":{"system":"sec-edgar","filing":"0000899243-21-014393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924321014393/doc4.xml","form_type":"4"}},{"id":2764835,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-01T22:23:14.000Z","date":"2020-12-21","kind":"grant","acquired":true,"shares":5362888,"price":1.3985,"value":7499998.868,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F5","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"Atlas Opportunity I\"). Atlas Venture Associates Opportunity I, L.P. (\"Associates I\") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC (\"Associates I LLC\") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5362888,"derivative":{"underlying":"Common Stock","underlying_shares":749634},"source":{"system":"sec-edgar","filing":"0000899243-21-014393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924321014393/doc4.xml","form_type":"4"}},{"id":2764834,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T22:23:14.000Z","date":"2021-03-30","kind":"exercise","acquired":true,"shares":749634,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"Atlas Opportunity I\"). Atlas Venture Associates Opportunity I, L.P. (\"Associates I\") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC (\"Associates I LLC\") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":749634,"source":{"system":"sec-edgar","filing":"0000899243-21-014393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924321014393/doc4.xml","form_type":"4"}},{"id":2764833,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T22:23:14.000Z","date":"2021-03-30","kind":"exercise","acquired":true,"shares":1099118,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"Associates XI\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"Associates XI LLC\") is the general partner of Associates XI. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1268213,"source":{"system":"sec-edgar","filing":"0000899243-21-014393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924321014393/doc4.xml","form_type":"4"}},{"id":2764832,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T22:23:14.000Z","date":"2021-03-30","kind":"exercise","acquired":true,"shares":2901609,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas X\"). Atlas Venture Associates X, L.P. (\"Associates X\") is the general partner of Atlas X. Atlas Venture Associates X, LLC (\"Associates X LLC\") is the general partner of Associates X. The Reporting Person is a member of Associates X LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2901609,"source":{"system":"sec-edgar","filing":"0000899243-21-014393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924321014393/doc4.xml","form_type":"4"}},{"id":2827346,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-01T18:59:47.000Z","date":"2021-02-26","kind":"sale","acquired":false,"shares":501945,"price":60.2909,"value":30262715.8005,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\"). Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00219 - $60.50021, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1113376,"source":{"system":"sec-edgar","filing":"0001104659-21-029884","document":"tm218286-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465921029884/tm218286-1_4seq1.xml","form_type":"4"}},{"id":2933444,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-23T23:07:27.000Z","date":"2020-12-22","kind":"sale","acquired":false,"shares":2700,"price":25.8825,"value":69882.75,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Associates VIII, L.P. (\"AVA VIII LP\"). The shares were previosly received by AVA VIII LP in a pro-rata stock distribution pursuant to a Rule 10b5-1 plan established by Atlas Venture Fund VIII, L.P. (\"Atlas VIII\"). Atlas Venture Associates VIII, Inc. (\"AVA VIII INC\") is the general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by AVA VIII LP, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.88 - $25.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares sold by Atlas Venture Associates VIII, L.P. (\"AVA VIII LP\"). The shares were previosly received by AVA VIII LP in a pro-rata stock distribution pursuant to a Rule 10b5-1 plan established by Atlas Venture Fund VIII, L.P. (\"Atlas VIII\"). Atlas Venture Associates VIII, Inc. (\"AVA VIII INC\") is the general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by AVA VIII LP, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":43940,"source":{"system":"sec-edgar","filing":"0001104659-20-139273","document":"tm2039292d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465920139273/tm2039292d1_4seq1.xml","form_type":"4"}},{"id":2933443,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-23T23:07:27.000Z","date":"2020-12-22","kind":"sale","acquired":false,"shares":79865,"price":25.0421,"value":1999987.3165,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Associates VIII, L.P. (\"AVA VIII LP\"). The shares were previosly received by AVA VIII LP in a pro-rata stock distribution pursuant to a Rule 10b5-1 plan established by Atlas Venture Fund VIII, L.P. (\"Atlas VIII\"). Atlas Venture Associates VIII, Inc. (\"AVA VIII INC\") is the general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by AVA VIII LP, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 - $25.66, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares sold by Atlas Venture Associates VIII, L.P. (\"AVA VIII LP\"). The shares were previosly received by AVA VIII LP in a pro-rata stock distribution pursuant to a Rule 10b5-1 plan established by Atlas Venture Fund VIII, L.P. (\"Atlas VIII\"). Atlas Venture Associates VIII, Inc. (\"AVA VIII INC\") is the general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by AVA VIII LP, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":46640,"source":{"system":"sec-edgar","filing":"0001104659-20-139273","document":"tm2039292d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465920139273/tm2039292d1_4seq1.xml","form_type":"4"}},{"id":2933442,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-23T23:07:27.000Z","date":"2020-12-21","kind":"sale","acquired":false,"shares":56536,"price":25.5046,"value":1441928.0656,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Associates VIII, L.P. (\"AVA VIII LP\"). The shares were previosly received by AVA VIII LP in a pro-rata stock distribution pursuant to a Rule 10b5-1 plan established by Atlas Venture Fund VIII, L.P. (\"Atlas VIII\"). Atlas Venture Associates VIII, Inc. (\"AVA VIII INC\") is the general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by AVA VIII LP, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.14 - $26.09, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares sold by Atlas Venture Associates VIII, L.P. (\"AVA VIII LP\"). The shares were previosly received by AVA VIII LP in a pro-rata stock distribution pursuant to a Rule 10b5-1 plan established by Atlas Venture Fund VIII, L.P. (\"Atlas VIII\"). Atlas Venture Associates VIII, Inc. (\"AVA VIII INC\") is the general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by AVA VIII LP, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":126505,"source":{"system":"sec-edgar","filing":"0001104659-20-139273","document":"tm2039292d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465920139273/tm2039292d1_4seq1.xml","form_type":"4"}},{"id":2999450,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-10-27T21:37:45.000Z","date":"2020-10-27","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option will vest and become exercisable in full on October 27, 2021 subject to the Reporting Person's continued service as a director through the vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person is a member of Atlas Venture Associates IX, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership to the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":7500,"derivative":{"exercise_price":13.52,"expiration_date":"2030-10-27","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-20-029338","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000089924320029338/doc4.xml","form_type":"4"}},{"id":3045738,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-28T00:14:16.000Z","date":"2020-08-27","kind":"sale","acquired":false,"shares":10097,"price":14.3822,"value":145217.0734,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund VIII, L.P. (\"Atlas VIII\").  Atlas Venture Associates VIII, L.P. (\"AVA VIII LP\") is the general partner of Atlas VIII.  Atlas Venture Associates VIII, Inc. (\"AVA VIII INC\") is the general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $14.25 - $14.61, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held directly by Atlas VIII.  The sole general partner of Atlas VIII is AVA VIII LP.  AVA VIII INC is the sole general partner of AVA VIII LP.  Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":3833122,"source":{"system":"sec-edgar","filing":"0001104659-20-099718","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465920099718/a4.xml","form_type":"4"}},{"id":3045737,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-28T00:14:16.000Z","date":"2020-08-26","kind":"sale","acquired":false,"shares":44381,"price":14.7979,"value":656745.5999,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund VIII, L.P. (\"Atlas VIII\").  Atlas Venture Associates VIII, L.P. (\"AVA VIII LP\") is the general partner of Atlas VIII.  Atlas Venture Associates VIII, Inc. (\"AVA VIII INC\") is the general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $14.60 - $15.09, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held directly by Atlas VIII.  The sole general partner of Atlas VIII is AVA VIII LP.  AVA VIII INC is the sole general partner of AVA VIII LP.  Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":3843219,"source":{"system":"sec-edgar","filing":"0001104659-20-099718","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465920099718/a4.xml","form_type":"4"}},{"id":3045736,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-28T00:14:16.000Z","date":"2020-08-25","kind":"sale","acquired":false,"shares":34410,"price":15.0003,"value":516160.323,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund VIII, L.P. (\"Atlas VIII\").  Atlas Venture Associates VIII, L.P. (\"AVA VIII LP\") is the general partner of Atlas VIII.  Atlas Venture Associates VIII, Inc. (\"AVA VIII INC\") is the general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $15.00 - $15.01, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held directly by Atlas VIII.  The sole general partner of Atlas VIII is AVA VIII LP.  AVA VIII INC is the sole general partner of AVA VIII LP.  Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":3887600,"source":{"system":"sec-edgar","filing":"0001104659-20-099718","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000110465920099718/a4.xml","form_type":"4"}},{"id":3104545,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-19T20:44:56.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 18, 2020 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":19000,"derivative":{"exercise_price":20.72,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001209191-20-037964","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000120919120037964/doc4.xml","form_type":"4"}}],"next_cursor":"2020-06-19T20:44:56.000000Z,3104545"}